ReviewDrugs2004
Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients.
Review in Drugs, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 52 citations in OpenAlex.
- Inhibition of hepatic gluconeogenesis in type 2 diabetes by metformin: complementary role of nitric oxide.Medical gas research · 2025Review
- Improvement of coronary microcirculation in acute myocardial ischemia rats using a nanoscale carrier SiODrug delivery and translational research · 2025Article
- Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Review
- The ATP sensitive potassium channel (KFrontiers in molecular neuroscience · 2023Review
- Adverse event profiles of microscopic colitis in the Japanese Adverse Drug Event Report (JADER) database.Scientific reports · 2022Article
- Evaluation of the effects of nicorandil and its molecular precursor (without radical NO) on proliferation and apoptosis of 786-cell.Cytotechnology · 2013Article
- Potassium channels: a review of broadening therapeutic possibilities for neurological diseases.Journal of neurology · 2013Review
- Recurrence of Takotsubo cardiomyopathy with coronary slow flow phenomenon.Journal of cardiology cases · 2012Article
- Stable angina pectoris: antianginal therapies and future directions.Nature reviews. Cardiology · 2011Review
- [New agents for the therapy of angina pectoris].Der Internist · 2011Review
- Review
- Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.Vascular health and risk management · 2010Review
- Medical therapy versus percutaneous coronary interventions for patients with stable and unstable coronary artery disease.Current atherosclerosis reports · 2008Review
- Recent developments in nitric oxide donor drugs.British journal of pharmacology · 2007Review
- K(ATP) channel therapeutics at the bedside.Journal of molecular and cellular cardiology · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nicorandil (Adancor, Angicor, Dancor, Nikoril [Europe], Ikorel [Europe and Oceania], Sigmart [Japan, Korea and Taiwan]) is an adenosine triphosphate (ATP)-sensitive potassium (KATP) channel agonist with nitrate-like properties used in the management of stable angina pectoris. With well established monotherapeutic antianginal activity and a beneficial effect (when added to optimal antianginal therapy) on clinical outcomes in high-risk patients with stable angina, twice-daily oral nicorandil is a useful alternative or addition to other antianginal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.